ArticleBMC cancer2025

High-dose third-generation EGFR-TKIs combined with intrathecal pemetrexed in advanced EGFR-mutant NSCLC with leptomeningeal metastases following EGFR-TKI therapy.

Shugui Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.